Get the Stockscreener App
2.33
2.92%
-0.07
After Hours:
2.32
-0.01
-0.43%
Oramed Pharmaceuticals Inc stock is traded at $2.33, with a volume of 74,361.
It is down -2.92% in the last 24 hours and down -1.27% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$2.40
Open:
$2.35
24h Volume:
74,361
Relative Volume:
0.62
Market Cap:
$95.54M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
21.18
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
+6.39%
1M Performance:
-1.27%
6M Performance:
+5.43%
1Y Performance:
-0.21%
1-Day Range:
$2.3296
$2.40
1-Week Range:
$2.1883
$2.49
52-Week Range:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.33 | 95.64M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Forecasting Oramed Pharmaceuticals Inc. price range with options dataMarket Growth Report & Expert Approved Momentum Trade Ideas - newser.com
Is Oramed Pharmaceuticals Inc. (OJU1) stock vulnerable to rate hikesQuarterly Earnings Summary & Weekly Sector Rotation Insights - newser.com
When is the best time to exit Oramed Pharmaceuticals Inc.July 2025 Market Mood & Weekly Momentum Picks - newser.com
Is Oramed Pharmaceuticals Inc. stock a top pick in earnings season2025 Pullback Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Using Ichimoku Cloud for Oramed Pharmaceuticals Inc. technicalsPortfolio Risk Summary & Short-Term Swing Trade Alerts - newser.com
Will Oramed Pharmaceuticals Inc. (OJU1) stock issue positive guidanceEarnings Recap Report & Weekly Top Gainers Alerts - newser.com
Will Oramed Pharmaceuticals Inc. benefit from macro trendsWeekly Trade Recap & Precise Trade Entry Recommendations - newser.com
What sentiment indicators say about Oramed Pharmaceuticals Inc. stock2025 Volatility Report & Daily Profit Maximizing Tips - newser.com
What recovery options are there for Oramed Pharmaceuticals Inc.Treasury Yields & Long-Term Growth Plans - newser.com
Custom watchlist performance reports with Oramed Pharmaceuticals Inc.2025 Analyst Calls & Weekly High Momentum Picks - newser.com
Visualizing Oramed Pharmaceuticals Inc. stock with heatmapsJuly 2025 Outlook & Weekly Top Gainers Alerts - newser.com
Is Oramed Pharmaceuticals Inc. stock a defensive play in 20252025 Top Gainers & Scalable Portfolio Growth Methods - newser.com
Volume Summary: Is Oramed Pharmaceuticals Inc. stock a defensive play in 2025Portfolio Gains Summary & Technical Pattern Recognition Alerts - Fundação Cultural do Pará
Published on: 2025-11-14 03:25:03 - newser.com
Oramed: Q3 Earnings Snapshot - New Haven Register
Will Oramed Pharmaceuticals Inc. stock continue upward momentum2025 Market WrapUp & Long-Term Capital Growth Strategies - newser.com
Ranking Oramed Pharmaceuticals Inc. among high performing stocks via toolsWeekly Trade Analysis & AI Enhanced Market Trend Forecasts - newser.com
Tools to assess Oramed Pharmaceuticals Inc.’s risk profileGDP Growth & Reliable Momentum Entry Alerts - newser.com
Will Oramed Pharmaceuticals Inc. (OJU1) stock maintain strong growthEarnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com
Applying sector rotation models to Oramed Pharmaceuticals Inc.2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
How Oramed Pharmaceuticals Inc. stock reacts to global recession fearsJuly 2025 Market Mood & Fast Exit and Entry Strategy Plans - newser.com
What does recent volatility data suggest for Oramed Pharmaceuticals Inc.Market Weekly Review & Fast Exit/Entry Strategy Plans - newser.com
How Oramed Pharmaceuticals Inc. (OJU1) stock correlates with oil marketsWeekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Published on: 2025-11-12 11:02:43 - newser.com
Can technical indicators confirm Oramed Pharmaceuticals Inc.’s reversalJuly 2025 Spike Watch & Weekly Market Pulse Alerts - newser.com
Leading vs lagging indicators on Oramed Pharmaceuticals Inc. performanceTrade Volume Report & Weekly Setup with ROI Potential - newser.com
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):